Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05980117 · ClinicalTrials.gov registry record · Phase 4
Remimazolam for Cataract Surgery
A Phase 4 study of Cognitive Impairment and Cataract Surgery, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05980117 is a Phase 4 study of Cognitive Impairment and Cataract Surgery that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 120 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05980117, a Phase 4 study of Cognitive Impairment and Cataract Surgery, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess any post operative cognitive changes following benzodiazepine administration during cataract surgery. The investigators will compare effects of Midazolam vs. Remimazolam on cognition at the time of discharge from the post operative care unit and the next day following surgery. Cognitive changes will be assessed by administration of Montreal Cognitive Assessment (MoCA). Participants will: 1. Complete MoCA testing prior to surgery 2. Randomize in either Midazolam or study drug Remimazolam 3. Complete MoCA testing after surgery at the time of discharge in the post anesthesia care unit and the next day of surgery at the time of post operative surgical visit. 4. Complete Patient Satisfaction Survey at the time of discharge from the Post Anesthesia Care Unit (PACU)
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Remimazolam
Study Locations (1)
California
- Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05980117
The ClinicalTrials.gov registry entry for NCT05980117 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (82% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.
NCT05980117 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05980117 about?
NCT05980117 is a clinical study titled "Remimazolam for Cataract Surgery". The goal of this study is to assess any post operative cognitive changes following benzodiazepine administration during cataract surgery. The investigators will compare effects of Midazolam vs. Remimazolam on cognition at the time of discharge from the post operative care unit and the next day follo...
What is the current status of trial NCT05980117?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2025-03-10. Estimated completion is 2026-01.
What conditions does trial NCT05980117 study?
This clinical trial studies the following conditions: Cognitive Impairment, Cataract Surgery.
What interventions are being tested in trial NCT05980117?
The interventions under investigation include: Midazolam (DRUG), Remimazolam (DRUG).
Who is sponsoring clinical trial NCT05980117?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05980117 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.